1/1
RevImmune 2.png
T-CELL TECHNOLOGY & DEVELOPMENT

Our Technology, Pipeline & People

OUR TECHNOLOGY

RevImmune’s platform technology is focused on IL-7, which plays a key role in T cell development, expansion, proliferation and mobilization. Importantly, IL-7 plays such a central role in regard to naïve T cells as well as memory T cells.  

 

Our product – CYT107 – is a glycosylated form of IL-7 which is very well tolerated in patients. 

 

A large body of scientific literature documents the central role of IL-7.
FOR EXAMPLE

Drum Nat Rev Immunology IL7 2019.pdf​

JCI Insight.pdf

Perales IL7 Blood bone marrow reconstitution.pdf

IL7 signaling Nat Med 2009.pdf

CYT107 is currently in multiple Phase 2 clinical trials to treat multiple diseases or conditions, with an additional trial pending.

 

To date, we have treated over 450 patients with CYT107.  

 

The CYT107 safety profile is excellent: some patients may experience a minor rash, but many do not. 

RevImmune's goal is to successfully trial CYT107 on COVID-19 patients as part of a global effort to treat the disease.

OUR PIPELINE

OUR PEOPLE

Dr. Kenneth Remy

SCIENTIFIC COLLABORATOR

Michel Morre

CHIEF SCIENTIFIC OFFICER

Dr. Richard Hotchkiss

SCIENTIFIC COLLABORATOR

© 2020 RevImmune. All Rights Reserved. Contact Us.

United States and Europe.